Hydroxymethylnitrofurazone lymphatic uptake with nanostructured lipid carrier after oral administration in rats

Nanomedicine (Lond). 2024 Feb;19(4):293-301. doi: 10.2217/nnm-2023-0263. Epub 2024 Jan 25.

Abstract

Background: Leishmaniasis, caused by the protozoan Leishmania sp., infects phagocyte cells present in lymphatic organs. This study demonstrates the influence of nanostructured lipid carrier-loaded hydroxymethylnitrofurazone (NLC-NFOH) on lymphatic uptake using a chylomicron-blocking flow model in rats. Method: Lymphatic uptake of NFOH was assessed 1 h after oral administration of dimethyl sulfoxide with NFOH or NLC-NFOH with and without cycloheximide pretreatment. Result: Dimethyl sulfoxide with NFOH and NLC-NFOH showed NFOH serum concentrations of 0.0316 and 0.0291 μg/ml, respectively. After chylomicron blocking, NFOH was not detected. Conclusion: Despite log P below 5, NFOH was successfully taken up by the lymphatic system. Long-chain fatty acids and particle size might be main factors in these findings. NLC-NFOH is a promising and convenient platform for treating leishmaniasis via oral administration.

Keywords: chylomicrons; cycloheximide; hydroxymethylnitrofurazone; lymphatic system; nanostructured lipid carrier.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Chylomicrons
  • Dimethyl Sulfoxide
  • Drug Carriers
  • Leishmaniasis*
  • Nanostructures*
  • Nitrofurazone / analogs & derivatives*
  • Particle Size
  • Rats

Substances

  • hydroxymethylnitrofurazone
  • Dimethyl Sulfoxide
  • Chylomicrons
  • Drug Carriers
  • Nitrofurazone